Balanced news tone
News Sentiment
INVA sentiment intelligence
Innoviva Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
78/100 classification confidence.
directly relevant articles
high-authority source matches
-1.1% over one week, +0.1% over four weeks, trend active, and materially above fair value.
H.C. Wainwright reiterates Innoviva stock rating on drug delivery platform By Investing.com
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
INNOVIVA INC (NASDAQ:INVA) Scores as a Value Stock with Strong Fundamentals
Innoviva Inc (INVA) has been identified as a strong value stock due to its high fundamental ratings across valuation, profitability, health, and growth metrics. The company boasts a cheap valuation with a P/E of 6.01, robust profitability shown by a 119.88% profit margin, excelle
- Tone
- Positive 90/100
- Event
- Earnings
- Published
- 25 May 2026 10:38
- Source
- ChartMill
The Technical Signals Behind (INVA) That Institutions Follow
This article from Stock Traders Daily analyzes the technical signals for Innoviva Inc. (NASDAQ: INVA), highlighting weak near and mid-term sentiment but a strong long-term outlook. It identifies resistance testing, an exceptional short setup with a 29.0:1 risk-reward ratio, and p
- Tone
- Negative 37/100
- Event
- Guidance
- Published
- 25 May 2026 01:10
- Source
- Stock Traders Daily
Innoviva (INVA) CFO adds ESPP shares and uses stock to pay taxes
Innoviva, Inc.'s CFO, Stephen Basso, engaged in routine equity activities, acquiring 1,123 shares through the company's Employee Stock Purchase Plan (ESPP) on May 15, 2026. Subsequently, on May 20, 2026, 559 shares were withheld to cover income taxes related to the vesting of pri
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 May 2026 20:39
- Source
- Stock Titan
Innoviva (INVA) CEO logs ESPP share grant and tax withholding on Form 4
Innoviva, Inc. CEO Pavel Raifeld reported routine equity compensation activity through a Form 4 filing. On May 15, he acquired 1,123 shares of common stock at no cost via the Employee Stock Purchase Plan, and on May 20, 1,130 shares were withheld by Innoviva to cover income taxes
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 May 2026 20:39
- Source
- Stock Titan
Innoviva (NASDAQ: INVA) CAO has shares withheld to cover tax obligations
Innoviva, Inc.'s Chief Accounting Officer, Marianne Zhen, had 1,127 shares of common stock withheld by the company to cover income tax obligations related to the quarterly vesting of prior equity grants. This transaction, executed on May 20, 2026, at $22.24 per share, was a tax-w
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 May 2026 20:39
- Source
- Stock Titan
Innoviva Board Shakeup Puts Governance And Valuation In Focus
Innoviva announced the resignation of two directors from its board, with Josephine Linden appointed as an independent director to the Audit Committee. This change puts corporate governance and valuation in focus, especially as the stock has seen significant long-term gains but re
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 May 2026 09:10
- Source
- Sahm
Innoviva (INVA) director receives RSU and stock option grants as board compensation
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 07:00
- Source
- Stock Titan
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
What Innoviva (INVA)'s Profit Rebound and ESOP Share Filing Means For Shareholders
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Is Innoviva (INVA) Pricing Look Compelling After Recent Share Price Softness?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 May 2026 07:00
- Source
- Market source
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty Strength
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- Market source
Innoviva: Q1 Earnings Snapshot
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 May 2026 21:43
- Source
- Associated Press
Innoviva (INVA) Tops Q1 Earnings Estimates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 May 2026 07:00
- Source
- Market source
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 May 2026 07:00
- Source
- Business Wire
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Mar 2026 07:00
- Source
- Market source
Is It Time To Revisit Innoviva (INVA) After Strong Multi Year Share Price Gains
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 24 Mar 2026 07:00
- Source
- Market source
Is It Time To Reassess Innoviva (INVA) After Its Strong Multi Year Share Price Run
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 28 Feb 2026 08:00
- Source
- Market source
Innoviva, Inc. (INVA): A Bull Case Theory
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Feb 2026 08:00
- Source
- Market source
US FDA approves Innoviva's oral antibiotic for gonorrhea
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Dec 2025 08:00
- Source
- Reuters
With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 09 Dec 2025 08:00
- Source
- simplywall.st
Innoviva's (NASDAQ:INVA) Solid Profits Have Weak Fundamentals
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Nov 2025 08:00
- Source
- simplywall.st
Innoviva, Inc.'s (NASDAQ:INVA) Shares Bounce 26% But Its Business Still Trails The Market
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Nov 2025 08:00
- Source
- simplywall.st
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 Nov 2025 08:00
- Source
- BioSpace
ETFs Investing in Innoviva, Inc. Stocks
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Aug 2025 09:13
- Source
- TradingView
Innoviva, Inc. Just Recorded A 54% EPS Beat: Here's What Analysts Are Forecasting Next
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 09 Aug 2025 07:00
- Source
- simplywall.st